Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GRAM does not have its own clinical results but has supported major public health efforts including COVID vaccine fill-finish for Johnson & Johnson/Janssen and BARDA contracts. It also supported the U.S. government’s monkeypox vaccine response with JYNNEOS fill-finish in partnership with HHS.
"In August 2020, BARDA awarded GRAM a one-year $160 million contract to provide fill and finish services for vaccines in response to the coronavirus pandemic... In September [2020], GRAM agreed with Janssen Pharmaceuticals... to support the manufacture of its SARS-CoV‑2 vaccine candidate..."
"In 2022 GRAM was contracted by HHS to fill and finish... JYNNEOS monkeypox vaccine..."
The company has expanded rapidly in recent years with multiple facility expansions to meet growing demand.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Grand River Aseptic Manufacturing.